UBS Group’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $147M | Sell |
646,747
-84,718
| -12% | -$15.1M | 0.02% | 868 |
|
|
2026
Q1 | $126M | Buy |
731,465
+342,638
| +88% | +$63.5M | 0.02% | 879 |
|
|
2025
Q4 | $77.6M | Sell |
388,827
-203,929
| -34% | -$37M | 0.01% | 1223 |
|
|
2025
Q3 | $92.7M | Sell |
592,756
-142,513
| -19% | -$22.6M | 0.01% | 1079 |
|
|
2025
Q2 | $112M | Sell |
735,269
-1,656,516
| -69% | -$221M | 0.02% | 883 |
|
|
2025
Q1 | $360M | Buy |
2,391,785
+2,056,123
| +613% | +$345M | 0.07% | 296 |
|
|
2024
Q4 | $62M | Buy |
335,662
+171,746
| +105% | +$33.1M | 0.01% | 1267 |
|
|
2024
Q3 | $32.3M | Buy |
163,916
+17,474
| +12% | +$3.63M | 0.01% | 1461 |
|
|
2024
Q2 | $30.3M | Buy |
146,442
+25,295
| +21% | +$5.73M | 0.01% | 1371 |
|
|
2024
Q1 | $32.8M | Buy |
121,147
+26,272
| +28% | +$6.27M | 0.01% | 1331 |
|
|
2023
Q4 | $22.4M | Sell |
94,875
-7,137
| -7% | -$1.4M | 0.01% | 1517 |
|
|
2023
Q3 | $20M | Sell |
102,012
-8,850
| -8% | -$1.82M | 0.01% | 1478 |
|
|
2023
Q2 | $23.3M | Buy |
110,862
+2,351
| +2% | +$468K | 0.01% | 1330 |
|
|
2023
Q1 | $21.9M | Buy |
108,511
+24,061
| +28% | +$5.45M | 0.01% | 1327 |
|
|
2022
Q4 | $18.4M | Buy |
84,450
+30,663
| +57% | +$6.7M | 0.01% | 1474 |
|
|
2022
Q3 | $10.6M | Buy |
53,787
+23,931
| +80% | +$5.17M | ﹤0.01% | 1738 |
|
|
2022
Q2 | $6.39M | Sell |
29,856
-22,669
| -43% | -$5.54M | ﹤0.01% | 2177 |
|
|
2022
Q1 | $14.9M | Sell |
52,525
-27,695
| -35% | -$8.54M | 0.01% | 1652 |
|
|
2021
Q4 | $30.2M | Sell |
80,220
-9,338
| -10% | -$3.63M | 0.01% | 1286 |
|
|
2021
Q3 | $37M | Buy |
89,558
+14,676
| +20% | +$6.1M | 0.01% | 1046 |
|
|
2021
Q2 | $27.7M | Buy |
74,882
+18,186
| +32% | +$6.07M | 0.01% | 1238 |
|
|
2021
Q1 | $16.4M | Sell |
56,696
-8,434
| -13% | -$2.34M | 0.01% | 1572 |
|
|
2020
Q4 | $16.3M | Buy |
65,130
+15,874
| +32% | +$3.78M | 0.01% | 1491 |
|
|
2020
Q3 | $11.2M | Buy |
49,256
+28,000
| +132% | +$5.81M | ﹤0.01% | 1573 |
|
|
2020
Q2 | $3.71M | Sell |
21,256
-637
| -3% | -$102K | ﹤0.01% | 2293 |
|
|
2020
Q1 | $2.76M | Sell |
21,893
-56,121
| -72% | -$8.42M | ﹤0.01% | 2447 |
|
|
2019
Q4 | $11.9M | Buy |
78,014
+43,182
| +124% | +$5.98M | ﹤0.01% | 1798 |
|
|
2019
Q3 | $4.61M | Buy |
34,832
+3,737
| +12% | +$501K | ﹤0.01% | 2462 |
|
|
2019
Q2 | $4.41M | Sell |
31,095
-3,531
| -10% | -$479K | ﹤0.01% | 2426 |
|
|
2019
Q1 | $5.03M | Buy |
34,626
+1,100
| +3% | +$145K | ﹤0.01% | 2200 |
|
|
2018
Q4 | $3.79M | Sell |
33,526
-5,673
| -14% | -$710K | ﹤0.01% | 2419 |
|
|
2018
Q3 | $5.27M | Buy |
39,199
+8,605
| +28% | +$1.06M | ﹤0.01% | 2303 |
|
|
2018
Q2 | $3.43M | Sell |
30,594
-1,090
| -3% | -$118K | ﹤0.01% | 2674 |
|
|
2018
Q1 | $3.38M | Buy |
31,684
+400
| +1% | +$43.1K | ﹤0.01% | 2675 |
|
|
2017
Q4 | $3.42M | Sell |
31,284
-7,021
| -18% | -$764K | ﹤0.01% | 2715 |
|
|
2017
Q3 | $4.14M | Buy |
38,305
+9,207
| +32% | +$946K | ﹤0.01% | 2399 |
|
|
2017
Q2 | $2.94M | Sell |
29,098
-3,572
| -11% | -$329K | ﹤0.01% | 2645 |
|
|
2017
Q1 | $2.94M | Sell |
32,670
-11,310
| -26% | -$961K | ﹤0.01% | 2572 |
|
|
2016
Q4 | $3.35M | Sell |
43,980
-17,547
| -29% | -$1.33M | ﹤0.01% | 2432 |
|
|
2016
Q3 | $5.13M | Sell |
61,527
-45,566
| -43% | -$3.82M | ﹤0.01% | 1996 |
|
|
2016
Q2 | $8.83M | Buy |
107,093
+28,578
| +36% | +$2.35M | 0.01% | 1480 |
|
|
2016
Q1 | $5.96M | Sell |
78,515
-12,526
| -14% | -$927K | ﹤0.01% | 1719 |
|
|
2015
Q4 | $7.32M | Buy |
91,041
+44,416
| +95% | +$3.2M | ﹤0.01% | 1658 |
|
|
2015
Q3 | $2.96M | Sell |
46,625
-12,833
| -22% | -$922K | ﹤0.01% | 2396 |
|
|
2015
Q2 | $4.18M | Sell |
59,458
-2,473
| -4% | -$183K | ﹤0.01% | 2258 |
|
|
2015
Q1 | $4.91M | Buy |
61,931
+31,829
| +106% | +$2.35M | ﹤0.01% | 2091 |
|
|
2014
Q4 | $1.92M | Buy |
+30,102
| New | +$1.89M | ﹤0.01% | 2947 |
|
Other funds holding CRL
AI
UBS Group's CRL Position: Q2 2026 in Review
UBS Group reduced its Charles River Laboratories (CRL) stake by 12% in Q2 2026, selling an estimated $15.1M and leaving 646,747 shares worth $147M. The position accounts for 0.02% of the portfolio, ranked #868.
UBS Group first reported a position in CRL in Q4 2014 and has held it in 47 quarters since. The position peaked at $360M in Q1 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- UBS Group held 646,747 shares of Charles River Laboratories worth $147M as of Q2 2026.
- UBS Group sold 84,718 Charles River Laboratories shares in Q2 2026, an estimated $15.1M.
- Charles River Laboratories made up 0.02% of UBS Group's portfolio in Q2 2026, its #868 holding.
- UBS Group first reported a position in Charles River Laboratories in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Charles River Laboratories position peaked at $360M in Q1 2025.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.